scholarly journals Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 494
Author(s):  
Ludovico Abenavoli ◽  
Tiziana Larussa ◽  
Alessandro Corea ◽  
Anna Caterina Procopio ◽  
Luigi Boccuto ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Science Studies ◽  
Wide Spectrum ◽  
Antioxidant Properties ◽  
Public Health Issue ◽  
Alcoholic Fatty Liver ◽  
Dietary Polyphenols ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD), which is emerging as a major public health issue worldwide, is characterized by a wide spectrum of liver disorders, ranging from simple fat accumulation in hepatocytes, also known as steatosis, to non-alcoholic steatohepatitis (NASH) and cirrhosis. At present, the pharmacological treatment of NAFLD is still debated and dietary strategies for the prevention and the treatment of this condition are strongly considered. Polyphenols are a group of plant-derived compounds whose anti-inflammatory and antioxidant properties are associated with a low prevalence of metabolic diseases, including obesity, hypertension, and insulin resistance. Since inflammation and oxidative stress are the main risk factors involved in the pathogenesis of NAFLD, recent studies suggest that the consumption of polyphenol-rich diets is involved in the prevention and treatment of NAFLD. However, few clinical trials are available on human subjects with NAFLD. Here, we reviewed the emerging existing evidence on the potential use of polyphenols to treat NAFLD. After introducing the physiopathology of NAFLD, we focused on the most investigated phenolic compounds in the setting of NAFLD and described their potential benefits, starting from basic science studies to animal models and human trials.

Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis

2017 ◽  
Vol 26 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Ahmed Elgebaly ◽  
Ibrahim A. I. Radwan ◽  
Mohamed M. AboElnas ◽  
Hamza H. Ibrahim ◽  
Moutaz F. M. Eltoomy ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Randomized Clinical Trials ◽  
Controlled Trial ◽  
Antioxidant Properties ◽  
Density Lipoprotein ◽  
Current Evidence ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Resveratrol is a potential treatment option for management of non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory, antioxidant properties, and calorie restriction-like effects. We aimed to synthesise evidence from published randomized clinical trials (RCTs) about the efficacy of resveratrol in the management of NAFLD.Methods: A computer literature search of PubMed, Scopus, Web of Science, and Cochrane Central was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup analysis and sensitivity analysis were conducted.Results: Four RCTs (n=158 patients) were included in the final analysis. The overall effect estimates did not favor resveratrol group in terms of: serum ALT (MD -2.89, 95%CI [-15.66, 9.88], p=0.66), serum AST (MD -3.59, 95%CI [-13.82, 6.63], p=0.49), weight (MD -0.18, 95%CI [-0.92, 0.55], p=0.63), BMI (MD -0.10, 95 %CI [-0.43, 0.24], p=0.57), blood glucose level (MD -0.27, 95%CI [-0.55, 0.01], p=0.05), insulin level (MD -0.12, 95%CI [-0.69, 0.46], p=0.69), triglyceride level (MD 0.04, 95%CI [-0.45, 0.53], p=0.87), and LDL level (MD 0.21, 95%CI [-0.41, 0.83], p=0.51). Pooled studies were heterogeneous.Conclusion: Current evidence is insufficient to support the efficacy of resveratrol in the management of NAFLD. Resveratrol does not attenuate the degree of liver fibrosis or show a significant decrease in any of its parameters.Abbreviations: ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: Aspartate aminotransferase; BMI: Body mass index; CK-18: Cytokeratin-18; CRP: C-reactive protein; HC: Head circumference; HDL: High density lipoprotein; IL-6: Interleukin-6; LDL: Low density lipoprotein; MD: Mean difference; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; RCT: Randomized Controlled Trial; RR: Relative risk; SIRT1: Silent information regulation 2 homologue 1; TNF-α: Tumor necrosis factor α; WC: Waist circumference; WHR: Waist hip ratio.

scholarly journals Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study

PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0260313
Author(s):  
Atul Goyale ◽  
Anjly Jain ◽  
Colette Smith ◽  
Margarita Papatheodoridi ◽  
Marta Guerrero Misas ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Positive Likelihood Ratio ◽  
Public Health Issue ◽  
Enzyme Linked Immunosorbent Assay ◽  
Roc Curve Analysis ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background/Aims Non-alcoholic fatty liver disease (NAFLD) represents a significant public health issue. Identifying patients with simple steatosis from those with non-alcoholic steatohepatitis (NASH) is crucial since NASH is correlated with increased morbidity and mortality. Serum-based markers, including adipokines and cytokines, are important in the pathogenesis and progression of NAFLD. Here we assessed the usefulness of such markers in patients with NAFLD. Methods This prospective, cross-sectional study included 105 adult patients with varying severity of NAFLD. Twelve serum-based markers were measured by 3 biochip platforms and 2 enzyme-linked immunosorbent assay (ELISA) methods. We also developed a NAFLD individual fibrosis index (NIFI) using the serum-based markers mostly correlated with fibrosis severity. Results Sixty-one out of 105 patients were male (58.1%) with mean age was 53.5 years. Higher Interleukin-6 (IL-6) increased (p = 0.0321) and lower Matrix Metalloproteinase-9 (MMP-9) serum levels (p = 0.0031) were associated with higher fibrosis as measured by Fibroscan® in multivariable regression analysis. Using receiver-operating characteristic (ROC) curve analysis for the NIFI, area under the curve for predicting Fibroscan values ≥ 7.2 kPa was 0.77 (95%CI: 0.67, 0.88, p<0.001), with sensitivity of 89.3%, specificity of 57.9% and a positive likelihood ratio of 2.8. Conclusions Increasing fibrosis severity in NAFLD is associated with differential expression of IL-6 and MMP-9. NIFI could be valuable for the prediction of advanced NAFLD fibrosis and potentially help avoid unnecessary interventions such as liver biopsy in low-risk patients.

scholarly journals A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation

Lab on a Chip ◽  
2019 ◽  
Vol 19 (18) ◽  
pp. 3022-3031 ◽  
Author(s):  
Beyza Bulutoglu ◽  
Camilo Rey-Bedón ◽  
Young Bok (Abraham) Kang ◽  
Safak Mert ◽  
Martin L. Yarmush ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Free Fatty Acid ◽  
Fatty Liver ◽  
Lipid Accumulation ◽  
Fatty Liver Disease ◽  
Wide Spectrum ◽  
Progressive Increase ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) involves a progressive increase of lipid accumulation. We created a microfluidic progressive NAFLD platform using free fatty acid gradients to capture the wide spectrum of disease conditions in a single continuous liver tissue.

scholarly journals Non-Alcoholic Fatty Liver Disease in First Degree Relatives of Patients with Nafld

2017 ◽  
Vol 2 (2) ◽  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Wide Spectrum ◽  
Alcoholic Fatty Liver ◽  
Benign Condition ◽  
First Degree Relatives ◽  
History Of ◽  
Diet And Lifestyle ◽  
Alcoholic Fatty Liver Disease

Non Alcoholic Fatty Liver Disease (NAFLD) includes a spectrum of hepatic pathology that resembles alcoholinduced liver disease but develops in individuals who deny a significant history of alcohol ingestion. NAFLD comprises a wide spectrum of liver damage, ranging from simple macrovesicular steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. The prevalence of NAFLD has doubled during last 20 years, whereas the prevalence of other chronic liver diseases has remained stable or even decreased. Moreover with increasing incidence and prevalence, the perception of NAFLD being a benign condition of little clinical significance is rapidly changing. Obesity, metabolic syndrome, type 2 diabetes (T2DM) and dyslipidemia are predisposing factors for NAFLD. All these are directly linked with diet and lifestyle of an individual and hence preventable and modifiable. The study was conducted to identify the prevalence of NAFLD among the first degree relatives of a patient already diagnosed with NAFLD. The study demonstrated the increased prevalence of NAFLD among the family members. Further risk factor analysis in the study strengthened the role of diet and lifestyle in the etiology of NAFLD.

Vanillic Acid and Non-Alcoholic Fatty Liver Disease: A Focus on AMPK in Adipose and Liver Tissues

2021 ◽  
Vol 27 ◽  
Author(s):  
Sepideh Shekari ◽  
Fatemeh Khonsha ◽  
Mohammad Rahmati-Yamchi ◽  
Hamid Reza Nejabati ◽  
Ali Mota
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Vanillic Acid ◽  
Fatty Liver Disease ◽  
Wide Spectrum ◽  
Special Focus ◽  
Protective Effects ◽  
Mice Model ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

: Non-alcoholic fatty liver disease (NAFLD), a growing health issue around the world, is defined as the presence of steatosis in the liver without any other detectable byproducts such as alcohol consumption which includes a wide spectrum of pathologies, such as steatohepatitis, cirrhosis, and hepatocellular carcinoma. A growing body of evidence indicates that the reduction in the 5' adenosine monophosphate-activated protein kinase (AMPK) activity, which could be activated by the consumption of the drugs, hormones, cytokines, and dietary restriction, is related to some metabolic disorders such as obesity, diabetes, PCOS, and NAFLD. Vanillic acid (VA), as an anti-inflammatory, anti-oxidative, anti-angiogenic and anti-metastatic factor, has protective effects on the liver as in two animal models of liver damage. It reduces serum levels of transaminases, inflammatory cytokines, and the accumulation of collagen in the liver and prevents liver fibrosis. Besides, it decreases body and adipose tissue weight in a mice model of obesity and, similar to the liver tissue, diminishes adipogenesis through the activation of AMPK. It has been reported that VA can target almost all of the metabolic abnormalities of NAFLD, such as hepatic steatosis, inflammation, and hepatic injury, at least partially through the activation of AMPK. Therefore, in this review, we will discuss the possible and hypothetical roles of VA in NAFLD, with a special focus on AMPK.

Dietary polyphenols and the odds of non-alcoholic fatty liver disease: A case-control study

2020 ◽  
Author(s):  
Ammar Salehi-sahlabadi ◽  
Farshad Teymoori ◽  
Masoumeh Jabbari ◽  
Aref Momeni ◽  
Amin Mokari-yamchi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Case Control Study ◽  
Case Control ◽  
Alcoholic Fatty Liver ◽  
Dietary Polyphenols ◽  
Alcoholic Fatty Liver Disease ◽  
Control Study

scholarly journals Association between edible mushroom intake and the prevalence of newly diagnosed non-alcoholic fatty liver disease: results from the Tianjin Chronic Low-Grade Systemic Inflammation and Health Cohort Study in China

2019 ◽  
Vol 123 (1) ◽  
pp. 104-112
Author(s):  
Shunming Zhang ◽  
Yeqing Gu ◽  
Min Lu ◽  
Jingzhu Fu ◽  
Qing Zhang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Antioxidant Properties ◽  
Low Grade ◽  
Inverse Association ◽  
Newly Diagnosed ◽  
Chinese Adults ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

AbstractAnimal studies have suggested that mushroom intake can alleviate non-alcoholic fatty liver disease (NAFLD) due to its anti-inflammatory and antioxidant properties. However, the association between mushroom intake and NAFLD is unknown in humans. We aimed to investigate the association of mushroom intake with NAFLD among Chinese adults. This is a cross-sectional study of 24 236 adults (mean (standard deviation) age: 40·7 (sd 11·9) years; 11 394 men (47·0 %)). Mushroom intake was assessed via a validated FFQ. Newly diagnosed NAFLD was identified based on the results of annual health examinations, including ultrasound findings and a self-reported history of the disease. Multiple logistic models were used to examine the association between mushroom intake and NAFLD. The prevalence of newly diagnosed NAFLD was 19·0 %. Compared with those consuming mushrooms less frequently (≤1 time/week), the fully adjusted OR of newly diagnosed NAFLD were 0·95 (95 % CI 0·86, 1·05) for those consuming 2–3 times/week and 0·76 (95 % CI 0·63, 0·92) for those consuming ≥4 times/week (Pfor trend = 0·01). The inverse association was consistent in subgroups defined by age, sex and BMI. In conclusion, higher mushroom intake was significantly associated with lower prevalence of NAFLD among Chinese adults. Future research is required to understand the causal association between mushroom intake and NAFLD.

scholarly journals Role of silymarin in the management of non-alcoholic fatty liver disease: Time to clear the mist

2019 ◽  
Vol 2 (5) ◽  
pp. 126
Author(s):  
Kuhu Roy ◽  
Uma Lyer
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Wide Spectrum ◽  
Therapeutic Drug ◽  
Alcoholic Fatty Liver ◽  
Metabolic Conditions ◽  
Drug Regimens ◽  
Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) has become a common chronic liver disease, global in nature. Occurring in individuals without a history of significant ethanol consumption, it encompasses a wide spectrum of hepatic disorders. It ranges from simple steatosis, to its advanced form, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis to even hepatocellular carcinoma. Infact, hepatocellular carcinoma (HCC) can also develop even in the absence of cirrhosis. The prevalence of NAFLD is on the rise primarily because of the already prevalent metabolic conditions like insulin resistance, type 2 diabetes, central obesity and dyslipidemia. Therefore, NAFLD is associated with adverse metabolic consequences. Other than the detrimental hepatic outcomes mentioned above, cases of NAFLD have a very high predisposition to cardiovascular disease. Therefore, management of NAFLD is of paramount importance. However, the challenge lies in the fact that there are no approved therapeutic drug regimens for the treatment of NAFLD. Currently, the standard care comprises of treating the underlying co-existing metabolic abnormalities along with a strong focus on lifestyle modification.Keywords: Non—alcoholic fatty liver disease, antioxidants, milk thistle, silymarin, flavonolignans, silibin

scholarly journals Prevalence of non-alcoholic fatty liver disease among obese children in North Kerala, India

2017 ◽  
Vol 4 (3) ◽  
pp. 1051
Author(s):  
Reetha G. ◽  
Mahesh P.
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Local Population ◽  
Tertiary Care ◽  
Public Health Issue ◽  
Obese Children ◽  
Alcoholic Fatty Liver ◽  
Alanine Amino Transferase ◽  
Alcoholic Fatty Liver Disease

Background: Obesity and related co-morbidities are increasing at an alarming pace all over the world. Non-alcoholic fatty liver disease (NAFLD) is the asymptomatic involvement of the liver mainly seen in obese individuals. NAFLD can progress to chronic liver disease and has to be identified early. The aims of our study were to determine the prevalence of nonalcoholic fatty liver disease among obese children in our local population. To determine the prevalence of abnormal liver enzymes in obese children.Methods: Cross sectional descriptive study in a tertiary care center among children aged 5-18 years for a 1 year period. NAFLD was diagnosed based on ultrasonography. Alanine amino transferase more than 40IU/l was taken as abnormal.Results: A total of 65 patients were enrolled in the study. The prevalence of NAFLD in the study group was 60%. 20% had elevated alanine amino transferase levels.Conclusions: The prevalence of fatty liver in Kerala is comparable to that in the West. Since this is a public health issue more population based studies are needed on a larger group to find out the exact magnitude of the problem.

Sign in / Sign up

Export Citation Format

Share Document